Abzu® selected partner for EU project Elegant North to create a new strategy for handling data on rare diseases.
To address the deficiency of treatments for rare diseases, the selected partners in project Elegant North will create a cross-border, rare disease data-sharing platform to foster cross-sector collaboration between researchers, companies, and healthcare systems.
Abzu® reveals insights in first-ever clinically viable Myc oncogene inhibitor by Peptomyc®.
Peptomyc used the QLattice and Abzu’s expertise in patient stratification to reveal early predictive response-biomarkers to treatment with OMO-103 in metastatic patients. The analysis by the QLattice was conducted on a very small clinical trial of 22 patients.
Abzu® awarded multi million EIC Accelerator grant.
Abzu will be applying the €2.5 million grant to the development of the Abzu AI platform, a user-friendly and easy-to-operate platform built on the QLattice engine that makes interpretable and explainable predictions widely accessible.
Abzu is named a 2022 Gartner “Cool Vendor”.
We’re thrilled to announce that Gartner has named Abzu a “Cool Vendor” in AI for excelling in explainability, fairness, and trustworthiness.
Abzu® appoints Mette Kirstine Agger as a board member.
Mette Kirstine Agger will help Abzu strengthen its position in life science and biotech by building a bridge between research and business development with her special experience in how new technologies can create and support growth and business opportunities within biotech and a wide range of other lines of industries.
Abzu announces a new location at the Switzerland Innovation Park Basel Area – Novartis Campus.
Basel Area Business & Innovation, a non-profit agency dedicated to helping startups, institutions, and companies find business success in the Basel Area, was integral in supporting Abzu’s settlement and facilitating access to the thriving ecosystem.
Abzu and Contera Pharma partner to design RNA therapeutics for rare diseases with explainable AI.
The two companies aim to have a rapid target screening application available this year, enabling Contera Pharma to advance better nucleic acid-based therapeutics.
Record-breaking investment in groundbreaking Danish AI: Abzu® announces a € 5.8 million seed round.
Prior to the record-breaking seed round in Denmark of € 5.8 M, Abzu raised a total of € 2.9 M. Abzu plans to accelerate commercialization within pharmaceutical drug discovery and mature its AI platform for application in other industry verticals.
Two Danish startups fight false news using artificial intelligence.
The transparent and explainable graph-based models from Abzu allow Byrd to precisely understand what inputs have been used to determine if content has been falsified.
Abzu® receives 1 million DKK grant for innovative, explainable AI.
Abzu’s proprietary innovation completely changes the way problems are solved by introducing a new standard of interpretability. This funding will be used for research and product development.
